Hsu Jason 4

What Happened
Director Jason Hsu received equity awards from Immix Biopharma on May 22, 2026: 6,250 restricted stock units (RSUs) granted at $0.00 and a 12,500-share derivative award (a stock option-type grant) reported at $0.00. These were awards/grants, not open-market purchases or sales, so no cash changed hands at grant.

Key Details

• Transaction date: 2026-05-22; Form filed: 2026-05-29 (appears later than the typical 2-business-day Form 4 deadline).
• Grants reported: 6,250 RSUs @ $0.00 (Acquired); 12,500 derivative (stock option) units @ $0.00 (Acquired).
• Shares owned after transaction: not specified on this Form 4.
• Footnotes of note:
  • F1: The 6,250 RSUs vest in full on the earlier of the one-year anniversary of grant or the Issuer’s 2027 annual meeting, subject to continued service.
  • F4: The 12,500-share option vests in substantially equal monthly installments over 12 months (or accelerates at the 2027 annual meeting), subject to continued board service.
  • F2/F3: Hsu is sole member of two LLCs referenced (VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC) and disclaims beneficial ownership of securities held by those entities except to the extent of pecuniary interest.

Context
These are standard compensation awards to a director (not a purchase or sale). RSUs and option grants typically align incentives with shareholder value but do not represent immediate cash proceeds or open-market buying. The filing date is later than usual for Form 4s, which are typically due within two business days of the transaction; late filing is a reporting issue but does not, by itself, indicate trading intent.